Hexarelin vs. Ipamorelin: Key Differences and Benefits

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Hexarelin (examorelin) and ipamorelin are synthetic ghrelin analogues that function as agonists of the growth hormone secretagogue receptor (GHS-R). Although structurally similar, with ipamorelin comprising a pentapeptide sequence and hexarelin a hexapeptide, subtle differences in amino acid composition confer distinct biological effects. Hexarelin has been associated with cardioprotective properties, whereas ipamorelin has demonstrated notable activity in promoting bone health. While both compounds activate the somatotropic axis and share overlapping pharmacological actions, their divergent secondary effects underscore the critical role of peptide sequence in determining functional specificity.

Comparative studies indicate that both ipamorelin and hexarelin elicit greater stimulation of endogenous growth hormone (GH) secretion than growth hormone–releasing hormone (GHRH) alone. Furthermore, they act synergistically with GHRH, producing substantial elevations in circulating GH concentrations even at relatively low doses. Their activity is further potentiated by sex steroids, such as testosterone, which augment the GH-releasing effects of GHS-R agonism. Prolonged administration, however, can result in partial and reversible tachyphylaxis, characterized by a decline in GH responsiveness likely mediated through altered GHS-R expression or density. Importantly, interruption of treatment generally restores baseline responsiveness, highlighting the adaptability of this regulatory axis.

Hexarelin Structure vs. Ipamorelin Structure

Peptide Sequence:

• Reported: Aib–His–D-2Nal–D-Phe–Lys
• Alternate (PubChem data): His–D-Trp(2-Me)–Ala–Trp–D-Phe–Lys

Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.87 g/mol
PubChem CID: 9831659
CAS Number: 170851-70-4

Data Source: PubChem

Peptide Sequence: Aib–His–D-2-Nal–D-Phe–Lys–NH₂

Molecular Formula: C₄₇H₅₈N₁₂O₆
Molecular Weight: 887.06 g/mol
PubChem CID: 6918297
CAS Number: 140703-51-1

Data Source: PubChem

Effects of Hexarelin and Ipamorelin on Body Composition and Growth Hormone Regulation

Given their origins as ghrelin derivatives, it is not surprising that hexarelin and ipamorelin support increases in lean body mass while helping to reduce fat. Studies in rat models of cachexia suggest that hexarelin plays a role in maintaining muscle cell health by regulating calcium balance and mitochondrial activity. In practical terms, this means that hexarelin helps muscle cells optimize how they generate and use energy. Ipamorelin, on the other hand, has been shown to influence nitrogen balance by reducing nitrogen loss in the liver. When combined with their effects on the growth hormone (GH) axis, these distinct mechanisms enhance muscle development and complement the actions of growth hormone and insulin-like growth factor 1.

Both compounds also influence appetite and dietary choices. As ghrelin receptor agonists, they fine-tune the GH response to food intake. Importantly, this action supports the natural pulsatile secretion of GH, rather than disrupting it. Animal studies highlight that maintaining the rhythm of GH release, even at higher overall levels, is crucial to avoiding negative side effects.

Ghrelin and its analogues work both in peripheral tissues and in the central nervous system (CNS). Within the CNS, ghrelin not only stimulates feeding behavior but also shapes food-related decision-making processes. It affects sensory perception, attention, and memory in ways that influence food preference, including smell, taste sensitivity, and reward pathways.

Interestingly, while natural ghrelin promotes preference for high-fat and high-sugar foods and encourages fat storage, hexarelin and ipamorelin show different effects. In animal models, ipamorelin improves blood sugar handling by directing glucose into muscle tissue rather than fat. This means that even when sugar intake rises, the outcome is more favorable to muscle growth than fat accumulation. Hexarelin demonstrates similar glucose-handling properties with the added benefit of lowering insulin resistance, which further limits fat storage.

Mechanisms of Ipamorelin in Bone Deposition and Skeletal Health

One of the distinctive advantages of ipamorelin is its ability to promote bone growth. Animal studies have demonstrated that ipamorelin can increase bone deposition by up to four times while also improving bone mineral density. Because of these effects, it is being investigated as a possible therapy for osteoporosis and bone loss linked to chronic illness.

Ipamorelin is also recognized for being one of the most selective growth hormone secretagogues. Evidence shows that it does not affect other hormones such as prolactin, adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), or follicle-stimulating hormone (FSH). Its influence on bone health, body composition, and related outcomes appears to work almost entirely through the growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis. Hexarelin, by contrast, is less selective and has been shown to cause minor increases in prolactin, ACTH, and cortisol secretion.

Role of Hexarelin in Preventing Cardiac Remodeling and Injury

Hexarelin is known to bind to the CD36 receptor, a property that appears to protect heart cells from damage by reducing apoptosis, or programmed cell death. In mouse studies, treatment with hexarelin prior to induced cardiac ischemia improved heart performance by supporting greater survival of cardiac muscle cells.

In addition to its immediate protective effects, hexarelin also contributes to long-term heart health by counteracting oxidative stress, a key factor in heart failure. By limiting this stress, hexarelin helps prevent adverse cardiac remodeling, which is responsible for structural changes that impair heart function after injury. Evidence further suggests that hexarelin influences the autonomic nervous system in the aftermath of cardiac injury, shifting the balance away from sympathetic overactivation toward parasympathetic activity. This shift can lower blood pressure, decrease heart rate, and ultimately reduce pathological remodeling. Animal research also shows that hexarelin treatment can lessen the extent of scar tissue formation in the heart following injury.

Hexarelin and Ipamorelin in Memory Enhancement and Neurogenesis

As discussed earlier, ghrelin has notable effects on memory. This likely represents an evolutionary adaptation, linking calorie-dense foods with positive memory formation while associating harmful or potentially toxic foods with negative memories. Such mechanisms would have been essential for survival, enabling organisms to remember where to find nourishing food and to avoid dangerous sources. Researchers extended this idea to explore whether ghrelin and its analogues could enhance broader aspects of memory and neurogenesis. Their reasoning was supported by evidence showing that activation of the growth hormone secretagogue receptor increases dendritic spine density and strengthens neuronal connections. In other words, stimulating this receptor appears to improve memory, suggesting that compounds such as ipamorelin and hexarelin could provide similar benefits.

Experimental findings support this hypothesis. Both ipamorelin and hexarelin have been shown to promote the growth of neurons (neurogenesis) and the expansion of synaptic networks. In mouse studies, hexarelin demonstrated particularly strong effects in stimulating neurogenesis within the sub-granular zone and dentate gyrus of the hippocampus. These brain regions are crucial not only for consolidating existing memories but also for forming new ones. Evidence suggests that hexarelin exerts these effects by enhancing the proliferation and survival of neuronal progenitor cells. Thus, while both compounds appear valuable for supporting memory and neurogenesis, hexarelin’s benefits in this area may be more pronounced when a direct comparison is made.

Growth Hormone Secretagogue Receptors and Pain Modulation

Ghrelin has long been recognized as a powerful anti-nociceptive agent. It plays a role in reducing both non-inflammatory visceral pain and somatic mechanical pain. More recent studies in rats suggest that ipamorelin exhibits similar effects. In these experiments, researchers also tested another ghrelin mimetic, HM01, but hexarelin was not included in the investigation. This raises the question of whether hexarelin also possesses pain-relieving properties.

The absence of direct testing does not necessarily imply a lack of effect. In fact, the study explored how blocking the ghrelin/growth hormone secretagogue receptor influenced the ability of ipamorelin to reduce pain. Findings showed that this receptor is essential for ipamorelin’s analgesic effects, and the same is true for ghrelin. This strongly suggests that the receptor itself is the key mediator of pain relief. By extension, it is reasonable to propose that any growth hormone secretagogue agonist may exert similar benefits. While further research is needed, it is highly plausible that hexarelin has strong analgesic properties. Its structural differences from ipamorelin could even mean that hexarelin provides greater efficacy in pain modulation, though this remains to be confirmed.

Restoring the GH/IGF-1 Axis: Potential Anti-Aging Roles of Hexarelin and Ipamorelin

Neither ipamorelin nor hexarelin has been directly studied for anti-aging purposes. However, it is well established that the decline of the GH/IGF-1 axis with age contributes to many of the physical and cognitive changes seen in older individuals. Since both compounds stimulate GH release and subsequently increase IGF-1 levels, there is reason to believe they may help lessen some age-related effects, even if they cannot completely stop the aging process. In animal models, this could mean improved function later in life and a reduced risk of disability often associated with advanced age.

Emerging evidence suggests that the decline of the GH/IGF-1 axis during aging may stem from reduced stimulation rather than an irreversible shutdown. Much like other biological systems, it appears to follow a “use it or lose it” principle. With aging, growth hormone–releasing hormone (GHRH) activity diminishes, leading to reduced GH output. At the same time, expression of the growth hormone secretagogue receptor (GHS-R) also decreases, limiting the natural effects of ghrelin and other endogenous agonists. Researchers propose that administering agents such as hexarelin or ipamorelin could “reawaken” this system, effectively jump-starting a pathway that has become less active with age.

The human body maintains balance between processes of buildup and breakdown. When the GH axis weakens, the balance shifts toward tissue breakdown, accelerating age-related decline. By stimulating this axis, ipamorelin and hexarelin may help restore equilibrium, supporting the preservation of tissues that would otherwise deteriorate with time.

Routes of Administration: Comparing Hexarelin and Ipamorelin

One of the key distinctions between ipamorelin and hexarelin lies in their methods of administration. Ipamorelin requires delivery through subcutaneous injection, whereas hexarelin is orally active. This gives hexarelin an advantage in terms of ease of use, especially in animal research, making it the more convenient option when other factors are comparable.

Comparative Overview of Hexarelin and Ipamorelin

Ipamorelin and hexarelin are both ghrelin mimetics that activate the growth hormone secretagogue receptor (GHS-R) to stimulate growth hormone (GH) release. Each produces significant increases in GH levels and acts synergistically with growth hormone–releasing hormone (GHRH), GHRH analogues, and sex hormones to further enhance secretion. Clinical studies have explored ipamorelin in phase II trials for improving bone density and treating post-operative ileus, while hexarelin has been evaluated in phase II trials for managing congestive heart failure. A notable difference between the two is that hexarelin is orally bioavailable, whereas ipamorelin requires subcutaneous injection. Both compounds also promote neurogenesis in the central nervous system and exert positive effects on body composition.

In summary, both agents are strong GHS-R agonists with robust GH-releasing properties. Their unique secondary actions, however, help distinguish them. Ipamorelin may be more relevant for bone-related research, while hexarelin holds promise for cardiovascular studies. Regardless of their differences, both have demonstrated a consistent record of safety and efficacy in numerous animal models.

References

1. Sirago G, Conte E, Fracasso F, Cormio A, Fehrentz JA, Martinez J, Musicco C, Camerino GM, Fonzino A, Rizzi L, Torsello A, Lezza AMS, Liantonio A, Cantatore P, Pesce V. Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci Rep. 2017 Oct 12;7(1):13017. doi: 10.1038/s41598-017-13504-y. PMID: 29026190; PMCID: PMC5638899.
2. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats https://doi.org/10.1016/j.ghir.2009.01.001.
3. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
4. Frutos MG, Cacicedo L, Fernández C, Vicent D, Velasco B, Zapatero H, Sánchez-Franco F. Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis. Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1140-52. doi: 10.1152/ajpendo.00236.2007. Epub 2007 Aug 7. PMID: 17684105.
5. Xu X, Ding F, Pang J, Gao X, Xu RK, Hao W, Cao JM, Chen C. Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2012 Sep 15;303(6):H703-11. doi: 10.1152/ajpheart.00257.2011. Epub 2012 Jul 27. PMID: 22842067.
6. Yuanjie Mao, Takeshi Tokudome, Ichiro Kishimoto, Kentaro Otani, Hiroshi Hosoda, Chiaki Nagai, Naoto Minamino, Mikiya Miyazato, Kenji Kangawa, Hexarelin Treatment in Male Ghrelin Knockout Mice after Myocardial Infarction, Endocrinology, Volume 154, Issue 10, 1 October 2013, Pages 3847–3854, https://doi.org/10.1210/en.2013-1291
7. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001 Oct;11(5):266-72. doi: 10.1054/ghir.2001.0239. PMID: 11735244.
8. Huang J, Li Y, Zhang J, Liu Y, Lu Q. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. Int Heart J. 2017 Apr 6;58(2):257-263. doi: 10.1536/ihj.16-241. Epub 2017 Mar 17. PMID: 28321024.
9. Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, Chen C. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017 Oct 1;158(10):3174-3187. doi: 10.1210/en.2017-00168. PMID: 28977588; PMCID: PMC5659698.
10. Tannenbaum GS, Epelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology. 2003 Mar;144(3):967-74. doi: 10.1210/en.2002-220852. PMID: 12586774.

Product available for research use only: